Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 611

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 3
Chunk 611
---
 University of Michigan and an M.D. from Wayne State University. He completed his Internal
Medicine internship and residency at Duke University Medical Center, and his Fellowship in Medical Oncology also at Duke.

Board
Leadership Structure

Our
Board is committed to promoting effective, independent governance of the Company. Our Board believes it is in the best interests of the
stockholders and the Company for the Board to have the flexibility to select the best director to serve as Chairman at any given time,
regardless of whether that director is an independent director or the Chief Executive Officer. Consequently, we do not have a policy
governing whether the roles of Chairman of the Board and Chief Executive Officer should be separate or combined. This decision is made
by our Board, based on the best interests of the Company considering the circumstances at the time.

Currently,
the offices of the Chairman of the Board and the Chief Executive Officer are held by two different people. Dr. Pomerantz is our independent,
non-executive Chairman of the Board and Mr. Meckler is our Chief Executive Officer. The Chief Executive Officer is responsible for the
day to day leadership and performance of the Company, while the Chairman of the Board provides guidance to the Chief Executive Officer
and sets the agenda for Board meetings and presides over meetings of the Board. We believe that separation of the positions reinforces
the independence of the Board in its oversight of the business and affairs of the Company, and creates an environment that is more conducive
to objective evaluation and oversight of management’s performance, increasing management accountability and improving the ability
of the Board to monitor whether management’s actions are in the best interests of the Company and its stockholders. Furthermore,
we believe that Dr. Pomerantz is especially suited to serve as our Chairman of the Board, in light of his significant strategic management
experience in the U.S. healthcare industry, which provides him with a unique perspective on the best methods of growth for a life sciences
company.

However,
our Board of Directors will continue to periodically review our leadership structure and may make such changes in the future as it deems
appropriate.

Role
of the Board in Risk Oversight

One
of the key functions of our Board is informed oversight of our risk management process. Our Board does not have a standing risk management
committee, but rather administers this oversight function directly through our Board as a whole, as well as through various standing
committees of our Board that address risks inherent in their respective areas of oversight. In particular, our